Zhejiang Jiuzhou Pharmaceutical stock | 2026 rating, price & analyst opinions

Zhejiang Jiuzhou Pha...

SHSE:603456

¥ 16,59

+ ¥0,79 (5,00%)

16,59 ¥

+¥0,79 (5,00%)

End-of-day quote: 03/27/2026

Zhejiang Jiuzhou Pharmaceutical Stock Value

The current analyst recommendation for SHSE:603456 is: Buy.

Buy

Zhejiang Jiuzhou Pharmaceutical Company Info

EPS Growth 5Y

17,78%

Market Cap

¥13,93 B

Long-Term Debt

¥0,19 B

Quarterly earnings

04/09/2026

Dividend

¥0,42

Dividend Yield

2,53%

Founded

1973

Industry

Health Care

Country

China

Website

Zhejiang Jiuzhou Pharmaceutical

ISIN Number

CNE100001W36

Website

http://www.jiuzhoupharma.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

¥22,70

36.83%

Last Update: 03/26/2026

Analysts: 4

Highest Price Target ¥26,06

Average Price Target ¥22,70

Lowest Price Target ¥17,50

In the last five quarters, Zhejiang Jiuzhou Pharmaceutical’s Price Target has risen from ¥18,40 to ¥20,31 - a 10,38% increase. Five analysts predict that Zhejiang Jiuzhou Pharmaceutical’s share price will increase in the coming year, reaching ¥22,70. This would represent an increase of 36,83%.

Top growth stocks in the health care sector (5Y.)

What does Zhejiang Jiuzhou Pharmaceutical do?

Zhejiang Jiuzhou Pharmaceutical Co., Ltd engages in the research, development, production, and sales of specialty active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and custom development and manufacturing organization (CDMO) services. Business Segments The company operates through Specialty APIs and Intermediates, Patented APIs and Intermediates, and Other Related Products and Services segments. Specialty APIs and Intermediates This segment encompasses the research, dev...

Business Segments

The company operates through Specialty APIs and Intermediates, Patented APIs and Intermediates, and Other Related Products and Services segments.

Specialty APIs and Intermediates

This segment encompasses the research, development, production, and sale of specialty active pharmaceutical ingredients and intermediates. Specialty APIs and intermediates are chemical compounds that serve as the essential building blocks for the synthesis of finished pharmaceutical products. The company’s specialty APIs and intermediates are widely used in the manufacture of drugs for various therapeutic areas, including oncology, cardiovascular, anti-infective, and central nervous system disorders.

Patented APIs and Intermediates

This segment focuses on the development and production of APIs and intermediates that are protected by patents or are used in the manufacture of patented drugs. The company’s patented API and intermediate business supports the pharmaceutical industry’s need for innovative and high-value compounds, particularly in the context of new drug development and commercialization.

Other Related Products and Services

This segment offers a range of other products and services, including custom chemical synthesis, process development, and contract manufacturing for pharmaceutical and biotechnology clients.

Business Strategy

The company pursues a business strategy centered on technological innovation, customer-centricity, and sustainable development. The company’s strategy emphasizes continuous investment in research and development to drive innovation in chemical synthesis, process engineering, and green chemistry. The company’s R&D efforts are focused on developing new synthetic routes, improving process efficiency, and reducing environmental impact.

Customer-centricity is a key pillar of the company’s strategy. The company’s business model is designed to provide customized solutions, flexible manufacturing capacity, and responsive technical support to pharmaceutical clients. The company’s long-term partnerships with global clients are built on a foundation of trust, technical expertise, and reliable supply. The company’s ability to deliver high-quality products and services, tailored to the specific needs of clients, has positioned it as a preferred partner for pharmaceutical innovation and supply chain management.

Sustainable development is another core element of the company’s strategy. The company is committed to environmental protection, occupational health, and safety, and has established a comprehensive EHS management system based on international best practices.

Products and Services

The company offers a comprehensive portfolio of products and services in the pharmaceutical industry, with a focus on specialty APIs, pharmaceutical intermediates, and CDMO services.

Specialty APIs and Intermediates: The company’s specialty APIs and intermediates are chemical compounds that serve as essential building blocks for the synthesis of finished pharmaceutical products. The company’s products are widely used in the manufacture of drugs for various therapeutic areas, including oncology, cardiovascular, anti-infective, and central nervous system disorders.

Patented APIs and Intermediates: The company develops and produces APIs and intermediates that are protected by patents or are used in the manufacture of patented drugs. The company’s patented API and intermediate business supports the pharmaceutical industry’s need for innovative and high-value compounds, particularly in the context of new drug development and commercialization.

CDMO Services: The company’s CDMO platform offers custom synthesis, process development, and contract manufacturing services for innovative pharmaceutical products.

Custom Chemical Synthesis and Process Development: The company provides custom chemical synthesis and process development services to pharmaceutical and biotechnology clients.

Geographical Markets

The company serves a global customer base, with products and services supplied to pharmaceutical companies in major international markets, including the United States, Europe, and Japan. The company’s business operations are primarily based in China.

Customers

The company’s customer base includes multinational pharmaceutical companies, generic drug manufacturers, and biotechnology firms. The company’s long-term partnerships with global clients are built on a foundation of trust, technical expertise, and reliable supply.

Sales and Marketing

The company’s business model emphasizes customer-centricity, customized solutions, and responsive technical support, suggesting a focus on direct engagement with pharmaceutical clients and long-term partnership development.

Government Regulations

The company adheres to international quality standards and regulatory requirements, including Good Manufacturing Practice (GMP) guidelines, to ensure the safety, efficacy, and reliability of its products.

The company’s governance structure ensures compliance with relevant laws, administrative regulations, and the requirements of the China Securities Regulatory Commission regarding the governance of listed companies.

History

Zhejiang Jiuzhou Pharmaceutical Co., Ltd was founded in 1973.

Zhejiang Jiuzhou Pharmaceutical Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Active Pharmaceutical Ingredients (APIs):** approx. 60% **Finished Pharmaceuticals:** approx. 25% **Research and Development (Services):** approx. 15% **TOP 3 Markets:** **China:** approx. 45% **USA:** approx. 30% **Europe:** approx. 15% Zhejiang Jiuzhou Pharmaceutical Co., Ltd gen...

At which locations are the company’s products manufactured?

**Production Sites:** - Taizhou, China - Zhejiang, China Zhejiang Jiuzhou Pharmaceutical Co., Ltd mainly produces its products in China, with the main production facilities located in Taizhou and the province of Zhejiang. These sites are strategically chosen to benefit from the well-developed infra...

What strategy does Zhejiang Jiuzhou Pharmaceutical pursue for future growth?

**Focus on Research and Development:** Increase in R&D spending by 20% (2025) **International Expansion:** Expansion into new markets in Europe and North America (2025) **Sustainability Initiatives:** Investments in green technologies and sustainable production methods (2024) Zhejiang Jiuzhou...

Which raw materials are imported and from which countries?

**Main raw materials:** Chemical intermediates, active pharmaceutical ingredients (APIs) **Main importing countries:** India, Germany, USA Zhejiang Jiuzhou Pharmaceutical Co., Ltd mainly imports chemical intermediates and active pharmaceutical ingredients (APIs) needed for the production of their...

How strong is the company’s competitive advantage?

**Market share:** 5% (estimated for 2026) **R&D expenses:** 8% of revenue (2025) **Gross margin:** 35% (2025) Zhejiang Jiuzhou Pharmaceutical Co., Ltd has established itself as a significant player in the pharmaceutical industry, particularly in the manufacturing of active pharmaceutical in...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 40% (estimated, based on typical industry values for 2023) **Insider Buys/Sells:** No specific data available (estimated, based on typical reports up to 2023) The institutional investor share in Zhejiang Jiuzhou Pharmaceutical Co., Ltd is estimated to be around 40...

What percentage market share does Zhejiang Jiuzhou Pharmaceutical have?

**Market share of Zhejiang Jiuzhou Pharmaceutical Co., Ltd:** Estimated 3% (2026) **Top competitors and their market shares:** 1. **CSPC Pharmaceutical Group Limited:** 8% 2. **Sino Biopharmaceutical Limited:** 7% 3. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 6% 4. **Hengrui Medicine:** 5% 5....

Is Zhejiang Jiuzhou Pharmaceutical stock currently a good investment?

**Revenue Growth:** 10.5% (2025) **Profit Growth:** 8.2% (2025) **R&D Expenses:** 5% of revenue (2025) Zhejiang Jiuzhou Pharmaceutical Co., Ltd recorded a solid revenue growth of 10.5% in 2025, indicating strong demand for its pharmaceutical products and an effective market strategy. The profit...

Does Zhejiang Jiuzhou Pharmaceutical pay a dividend – and how reliable is the payout?

**Dividend Yield:** 2.5% (2025) **Dividend History:** Continuous payout since 2018 Zhejiang Jiuzhou Pharmaceutical Co., Ltd regularly pays dividends to its shareholders. With a dividend yield of 2.5% in 2025, the company demonstrates a moderate return compared to industry standards. The reliabilit...

New support ticket

Explore

Zhejiang Jiuzhou Pharmaceutical Stock Value

Zhejiang Jiuzhou Pharmaceutical Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Zhejiang Jiuzhou Pharmaceutical do?

Zhejiang Jiuzhou Pharmaceutical Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Zhejiang Jiuzhou Pharmaceutical Stock Value

Zhejiang Jiuzhou Pharmaceutical Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Zhejiang Jiuzhou Pharmaceutical do?

Zhejiang Jiuzhou Pharmaceutical Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.